JP7562258B2 - Ｃｘｃｒ２抗体及びその使用 - Google Patents

Ｃｘｃｒ２抗体及びその使用 Download PDF

Info

Publication number
JP7562258B2
JP7562258B2 JP2019546398A JP2019546398A JP7562258B2 JP 7562258 B2 JP7562258 B2 JP 7562258B2 JP 2019546398 A JP2019546398 A JP 2019546398A JP 2019546398 A JP2019546398 A JP 2019546398A JP 7562258 B2 JP7562258 B2 JP 7562258B2
Authority
JP
Japan
Prior art keywords
seq
set forth
antibody
cxcr2
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019546398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508074A (ja
JP2020508074A5 (enExample
Inventor
マッケイ，チャールズ・リーアイ
ロバート，レミー・マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900656A external-priority patent/AU2017900656A0/en
Application filed by Monash University filed Critical Monash University
Publication of JP2020508074A publication Critical patent/JP2020508074A/ja
Publication of JP2020508074A5 publication Critical patent/JP2020508074A5/ja
Priority to JP2022205168A priority Critical patent/JP2023052023A/ja
Application granted granted Critical
Publication of JP7562258B2 publication Critical patent/JP7562258B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019546398A 2017-02-27 2018-02-27 Ｃｘｃｒ２抗体及びその使用 Active JP7562258B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022205168A JP2023052023A (ja) 2017-02-27 2022-12-22 Ｃｘｃｒ２抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900656 2017-02-27
AU2017900656A AU2017900656A0 (en) 2017-02-27 CXCR2 antibodies
PCT/IB2018/000253 WO2018154391A1 (en) 2017-02-27 2018-02-27 Cxcr2 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022205168A Division JP2023052023A (ja) 2017-02-27 2022-12-22 Ｃｘｃｒ２抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2020508074A JP2020508074A (ja) 2020-03-19
JP2020508074A5 JP2020508074A5 (enExample) 2021-04-08
JP7562258B2 true JP7562258B2 (ja) 2024-10-07

Family

ID=63253562

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019546398A Active JP7562258B2 (ja) 2017-02-27 2018-02-27 Ｃｘｃｒ２抗体及びその使用
JP2022205168A Pending JP2023052023A (ja) 2017-02-27 2022-12-22 Ｃｘｃｒ２抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022205168A Pending JP2023052023A (ja) 2017-02-27 2022-12-22 Ｃｘｃｒ２抗体及びその使用

Country Status (8)

Country Link
US (1) US11053319B2 (enExample)
EP (1) EP3585816A4 (enExample)
JP (2) JP7562258B2 (enExample)
KR (1) KR102673489B1 (enExample)
CN (1) CN110637034B (enExample)
AU (1) AU2018224391B2 (enExample)
CA (1) CA3054616A1 (enExample)
WO (1) WO2018154391A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585816A4 (en) 2017-02-27 2020-12-30 Monash University CXCR2 ANTIBODIES AND THEIR USES
BR112021001683A2 (pt) * 2018-08-01 2021-05-04 Cephalon, Inc. anticorpos anti-cxcr2 e usos dos mesmos
KR20220092859A (ko) 2019-09-04 2022-07-04 상하이테크 유니버시티 항-cxcr2 항체 및 이의 용도
EP4330286A4 (en) * 2021-04-26 2025-04-16 Kaohsiung Medical University ANTI-CXCR2 ANTIBODIES AND THEIR USES
KR102952495B1 (ko) * 2023-06-28 2026-04-16 (재) 스크립스코리아항체연구원 항-cxcr2 항체 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
JP2013545456A (ja) 2010-11-08 2013-12-26 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
WO2014170317A1 (en) 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2
JP2015524790A (ja) 2012-05-09 2015-08-27 ノバルティス アーゲー ケモカイン受容体結合性ポリペプチド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015169811A2 (en) 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof
EP3565596A4 (en) * 2017-01-05 2020-12-16 Brown University PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
EP3585816A4 (en) 2017-02-27 2020-12-30 Monash University CXCR2 ANTIBODIES AND THEIR USES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
JP2013545456A (ja) 2010-11-08 2013-12-26 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
JP2015524790A (ja) 2012-05-09 2015-08-27 ノバルティス アーゲー ケモカイン受容体結合性ポリペプチド
WO2014170317A1 (en) 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ｇｒｅｇ Ｗｉｎｔｅｒ ｅｔ ａｌ．，Ｉｍｍｕｎｏｌｏｇｙ Ｔｏｄａｙ，１９９３年，Ｖｏｌ．１４，Ｎｏ．６，ｐ．２４３－２４６
Ｊｅｆｆｅｒｓｏｎ Ｆｏｏｔｅ ｅｔ ａｌ．，Ｊｏｕｒｎａｌ ｏｆ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ，１９９２年，Ｖｏｌ．２２４，Ｎｏ．２，ｐ．４８７－４９９
Ｌｉｊｕｎ Ｗｕ ｅｔ ａｌ．，Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｂｉｏｌｏｇｉｃａｌ Ｃｈｅｍｉｓｔｒｙ，１９９６年１２月０６日，Ｖｏｌ．２７１，Ｎｏ．４９，ｐ．３１２０２－３１２０９
Ｒｏｎａｌｄ Ｓ Ｂｏｓｈｕｉｚｅｎ ｅｔ ａｌ．，ｍＡｂｓ，２０１４年１２月，Ｖｏｌ．６，Ｉｓｓｕｅ ６，ｐ．１４１５－１４２４

Also Published As

Publication number Publication date
WO2018154391A1 (en) 2018-08-30
JP2020508074A (ja) 2020-03-19
US11053319B2 (en) 2021-07-06
CN110637034A (zh) 2019-12-31
EP3585816A1 (en) 2020-01-01
AU2018224391B2 (en) 2025-06-12
JP2023052023A (ja) 2023-04-11
CA3054616A1 (en) 2018-08-30
AU2018224391A1 (en) 2019-09-19
CN110637034B (zh) 2023-10-10
KR20190123753A (ko) 2019-11-01
KR102673489B1 (ko) 2024-06-07
EP3585816A4 (en) 2020-12-30
US20190016809A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US12252536B2 (en) Caninized antibodies
US20220389114A1 (en) Pd-l1 antibodies binding canine pd-l1
KR102497259B1 (ko) Ｌａｇ―３ 항체, 이의 항원-결합 단편 및 이의 약학적 용도
US11479610B2 (en) Anti-IL1RAP antibody
TW202017945A (zh) 抗ｃｄ７３抗體、其抗原結合片段及應用
KR102942600B1 (ko) 항-pd-1 항체, 이의 항원-결합 단편 및 이의 약학적 용도
WO2021185273A1 (zh) 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
JP2023052023A (ja) Ｃｘｃｒ２抗体及びその使用
US20190352390A1 (en) Antibodies to il-37
TW202330600A (zh) Fap/cd40 結合分子及其醫藥用途
KR20130059396A (ko) 카드헤린-11의 ec1 도메인을 표적으로 하는 인간화 항체 및 관련 조성물 및 방법
CA3239307A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha 1
TW202313699A (zh) 新型抗ｓｉｒｐａ抗體
KR20210007041A (ko) 항-gm-csf 항체 및 이것의 사용
EP4108683A1 (en) Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof
CN119119280A (zh) FXII/FXIIa结合蛋白及其医药用途
JP7202011B2 (ja) 抗ｒａｍｐ２抗体
US20250270335A1 (en) Methods of treating inflammation
JP2026048674A (ja) 免疫グロブリン変異体
JP2026513302A (ja) 抗ｉｌ－２５抗体及びその使用方法
HK40106257A (zh) 新型抗sirpa抗体
WO2023023150A2 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
CN117510641A (zh) 靶向cd112r和tigit的双特异性抗体及其用途
CN117715932A (zh) 一种cdc平台抗体
HK1253584B (en) Antibody therapeutics that bind cd38

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221223

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230201

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230207

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230407

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240925

R150 Certificate of patent or registration of utility model

Ref document number: 7562258

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150